Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic

Sep 4, 2025Diabetes, obesity & metabolism

Using Semaglutide to Reach Weight Loss Goals: Real-World Results from an Online Clinic

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Mean weight loss at week 64 was 16.7% among 2694 participants in a digital weight loss program.

98% of participants achieved at least 5% weight loss.
82% of participants achieved at least 10% weight loss.
Weight loss outcomes were consistent across different BMI classes and doses.
The average semaglutide dose was 1.08 mg/week.
Participants were enrolled between January 2022 and September 2024, with retention rates of 1580, 712, and 465 at weeks 26, 52, and 64, respectively.

AI simplified

AIMS: To evaluate the effectiveness of an online multidisciplinary weight loss service combining individualised dosing with intensive behavioural therapy () in adults living with overweight or obesity.

MATERIALS AND METHODS: This retrospective cohort study included data from Danish participants enrolled in a digital weight loss programme via the Embla app between January 2022 and September 2024. The programme offered semaglutide with personalised dosing alongside evidence-based recommendations on nutrition, exercise and habits, delivered through IBT. All data collection and monitoring was conducted via the Embla app. The primary outcome was percentage change in body weight at week 64. Secondary outcomes included semaglutide dose, proportions achieving ≥5%, ≥10%, ≥15%, or ≥20% weight loss, and weight change by baseline BMI and dose.

RESULTS: The study included 2694 participants (78% women, mean age 46.8 ± 10.8 years, mean BMI 34.3 ± 4.8). At weeks 26, 52, and 64, the number of participants that remained in the study was: 1580, 712, and 465. Mean weight loss at week 64 was 16.7% (95% CI: -17.4 to -16.0) with a mean semaglutide dose of 1.08 mg/week (SD 0.54). A total of 98% achieved ≥5% and 82% achieved ≥10% weight loss. Weight change was consistent across BMI classes and medication doses.

CONCLUSIONS: Participants achieved clinically meaningful weight loss comparable to that seen in randomised trials, despite using lower semaglutide doses. These findings support the effectiveness of a personalised, treat-to-target approach integrating medical and behavioural obesity management in a digital setting.

TRIAL REGISTRATION: https://osf.io/86kmc/.

Key numbers

16.7%

Mean Weight Loss

Percentage change in body weight at week 64.

98 of 100

Participants Achieving Weight Loss

Proportion achieving ≥5% weight loss.

1.08 mg/week

Mean Dose

Average weekly dose at week 64.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief